0
The annual report highlights antimicrobial resistance patterns in bacteria isolated from humans (by CDC), raw retail meats (by FDA), and animals at slaughter (by USDA). The report also provides information derived from whole genome sequence data about resistance genes for all Salmonella and some Campylobacter isolates.
The points listed below summarize a selection of observations from the 2015 NARMS Integrated Report:
- Seventy-six percent of Salmonella isolated from humans had no resistance to any of the 14 antimicrobial drugs tested.
- Multidrug resistance (MDR) increased from 9 percent to 12 percent of human Salmonella, driven largely by an increase in combined resistance to ampicillin, streptomycin, sulfonamides, and tetracycline among Salmonella serotype I 4,[5],12:i:-.
- Ceftriaxone resistance either continued to decline or remained low in nontyphoidal Salmonella from all NARMS sources except turkey hazard analysis and critical control point (HACCP) samples, where the percent resistance in 2015 (15.7 percent) was the same as 2010 levels.
- While still rare, azithromycin resistance occurred in Salmonella, in some cases in strains with resistance to other antibiotics.
- Erythromycin resistance in Campylobacter coli increased three-to five-fold between 2011 and 2015 in isolates from humans (2.7 percent to 12.7 percent) and from chicken carcasses (3.4 percent to 12.8 percent).
- Transmissible quinolone resistance in Salmonella may be increasing. The underlying resistance traits reside on mobile genetic elements and therefore have the potential to be shared, either alone or together with other resistance genes, with susceptible strains of Salmonella.
- From 2014 to 2015, there was a decline from 73 percent to 57 percent in the proportion of retail ground turkey Salmonella isolates resistant to at least one antimicrobial. Historically, the majority of isolates from turkey sources have been resistant to at least one antimicrobial.
Monday October 23, 2017/ FDA/ United States.
https://www.fda.gov
